Collaboration across organizations, steady performance under pressure, and a drive toward a common goal — veterans like Birk Stathers bring an extraordinary foundation to FDA's work. This #VeteransDay, we're grateful for all who have served.
Ready to bring your skills to FDA? Explore opportunities: fda.gov/jobs
#FDAVeterans
Selfless service and a mission greater than yourself is not just a military value, it's the foundation of everything we do at FDA. We're honored to have veterans like Stacey Talley who carry that mindset into their work protecting public health every day. 🇺🇸
Your next mission awaits. Explore FDA careers: fda.gov/jobs
#FDAVeterans
Protecting the public health is a mission veterans understand. Darlise Henderson knew FDA was the right fit and we think other veterans will too. This #VeteransDay, we encourage all former service members to continue the charge and explore a career at FDA. fda.gov/jobs
#FDAVeterans
On #VeteransDay, we honor those who served — those who came home and those who did not. FDA is proud to have veterans like Brandon Finke among us, carrying that spirit of service into our public health mission every day. Thank you to all who have served. 🇺🇸
Ready to continue your service? Explore career opportunities at FDA: fda.gov/jobs
#FDAVeterans

ALT Sure, I can help with that. The image contains a banner with the FDA logo and the text "FDA Honors Those Who Served" at the top. Below is a photograph of a person in military uniform standing outside. There is a quote on the left side: "Veterans day is a day I reflect on those I served with and remember not only the ones that I returned with but also the ones who failed to return and the gratitude I have towards all of them." The quote is attributed to Brandon Finke.
On Veterans Day, the FDA proudly honors the men and women who have answered our nation's call to serve, in times of both peace and war. We recognize their service, sacrifice, and unwavering commitment to our country.
Today, Acting FDA Commissioner Kyle Diamantas spoke with @CancerResrch about FDA's role in the future of oncology research & development. We're committed to advancing safe, effective & innovative cancer treatments for patients.
Start watching at 9 min ⬇️
youtube.com/live/BtfhFNTaXes…
FDA has posted its FY27 BAA funding solicitations for extramural research supporting regulatory science & innovation! To learn more, join us for FDA BAA Industry Day on Dec. 8. Proposals are due by 5p ET, Jan. 22. Early applications are encouraged! fda.gov/science-research/adv…
4
6
5,186
This #VeteransDay, FDA's Oncology Center of Excellence & @VAResearch are teaming up with a new MOU. It supports collaboration on dose optimization, real-world evidence, & more — all to better serve #Veterans and protect public health. fda.gov/about-fda/oncology-c…
The first project under this MOU is already underway! Researchers are studying how variants in the DPYD gene affect the body's processing of the chemotherapy drug 5-fluorouracil (5-FU) in veterans with colorectal cancer.
Today, we are informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of GLP-1 RA medications.
NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking: visual defects such as blind spots, distortion of colors, blurriness, or tunnel vision.
Patients should contact their health care professional right away if they have any of these symptoms. fda.gov/drugs/drug-safety-co…
November is #DiabetesAwarenessMonth. Discover how 💉insulin #biosimilars can safely and effectively help treat health conditions such as diabetes: fda.gov/media/172979/downloa…
For the 95% of rare disease patients still without an approved treatment, FDA is working for you.
Acting Commissioner Kyle Diamantas shares how FDA is transforming rare disease drug development through the new Rare Disease Framework Initiative. Because every family deserves answers, action, and hope. fda.gov/news-events/fda-voic…
New infant formula data. Proposed nutrient updates. Our ongoing commitment to America’s babies.
FDA is sharing Operation Stork Speed testing results and proposing changes to some infant formula nutrient requirements.
Explore the data and weigh in on the proposal: fda.gov/food/infant-formula-…
Join the FDA Oncology Center of Excellence for a virtual Conversations on Cancer panel: “How CURE ID Can Help Find New Treatment Options for Rare Cancers” on Tuesday, Nov. 17 at 3 pm ET.
CURE ID collects real-world treatment experiences with repurposed drugs from patients, caregivers, and clinicians.
Watch on YouTube: youtube.com/live/8AB4zfKydog
#ConversationsOnCancer #FDAOncology
FDA just approved updated labeling for three more menopause hormone therapy (MHT) products, additionally we are also working to speed up production so that more women can get the treatments they need. This is part of our commitment to women’s health and directly supports a recent Executive Order signed by President Trump on October 19, 2026, that focused on advancing health outcomes for women at every stage of life.
hhs.gov/press-room/fda-advan…
As part of Operation Stork Speed, we also released new chemical contaminant testing data showing that most infant formula samples had low or non-detectable levels of contaminants. fda.gov/food/infant-formula-…
Today, FDA kicked off its Rare Disease Framework Initiative with a public meeting, co-hosted by @ReaganUdall. Thanks to all who joined for your input, candor & vision. With only 5% of rare diseases having an approved treatment, the status quo isn't enough — we must do more.
FDA Acting Commissioner @FDA_KyleD shared with the attendees that the “urgency of the need has not changed, but now we — the agency, drug developers, researchers, and patients — are ready to meet that need together.”
If you missed today's Rare Disease Framework Initiative meeting, the public docket is open until Dec. 11. Patients, advocates, industry & researchers are encouraged to submit comments & help shape rare disease drug development. federalregister.gov/document…
Reminder: Join the FDA Oncology Center of Excellence for a virtual Conversations on Cancer panel, Navigating Cancer Resources in the Digital Age, on Thursday, Oct. 29 at 2:00 PM ET. Learn how cancer patients and caregivers navigate online health information. Watch free:
youtube.com/live/r6IiucKFwrI…
#FDAOncology #ConversationsOnCancer
#DYK that nearly 1/2 of U.S. women over 40 have dense breast tissue — and that can make it harder to detect cancer on a #mammogram? This #BreastCancerAwarenessMonth, get the facts about #BreastDensity and why it matters from FDA Office of Women’s Health.
youtube.com/watch?v=E-JHJCT5…
Modernizing FDA's review process starts with listening. Acting Commissioner Kyle Diamantas joined @RareDiseases at the #NORDSummit Monday to discuss how patient voices are central to building a fit-for-purpose framework for #RareDisease therapies.
Acting @FDA Commissioner Kyle Diamantas, @FDA_KyleD, sat down for a fireside chat with #NORD President and CEO Pam Gavin to kick off the 2026 #NORDSummit, where he shared that the #FDA is committed to modernizing its review process and is relying on #RareDisease patient voices to help shape its fit-for-purpose regulatory framework. We appreciated the opportunity to break down what that will entail, and we're excited to be a partner in this crucial, timely mission.
The FDA is responsible for ensuring the U.S. seafood supply is safe, sanitary, wholesome, and properly labeled.
To support the America First Seafood Strategy, the agency published draft guidance to help companies proudly and accurately label seafood of U.S. origin.
If finalized, the guidance would provide examples of statements, such as “U.S.-Caught,” and graphics featuring the American flag to help consumers identify and choose U.S. seafood.
🤖 Made with AI


















